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Cancer results from cumulative alterations of the genetic
make-up of somatic cells that lead to aberrant expression,
mutation or deletion of proteins modulating cellular
proliferation, differentiation and survival. Through deregu-
lation of intracellular pathways, these defects allow cancer
cells to evade signals, which normally keep cell prolifera-
tion and survival tightly controlled [1]. Furthermore, the
tumor microenvironment facilitates processes, including
angiogenesis and matrix breakdown, that are necessary for
cancer cells to metastasize from the primary site to distant
organs. In the past 25 years our knowledge of the genetic
and epigenetic changes that contribute to cancer has
increased tremendously. In contrast, we are only beginning
to appreciate the complex interaction between tumor cells
and their stromal environment [2]. Our knowledge of
alterations in the cancer cell have, on the one hand, allowed
us to identify the signaling pathways that when disrupted
allow a cancer cell to escape from normal control mecha-
nisms. On the other hand, the aberrant processes have also
provided many therapeutic points for intervention, which is
the major topic of the current issue. We have chosen a
selection of potential molecules and pathways that are
altered in breast cancer and are under scrutiny as targeted
therapeutics. Some of these like the ERBB receptors have
yielded therapeutics that have already had clinical success;
while others are still in the experimental stages. With our
knowledge of the molecular alterations in breast cancer and
the increasing number of new targeted therapeutics, so-
called signal transduction inhibitors (STIs), the current
challenge is to select the best combination of STIs, or an
appropriate STI with a standard chemotherapy for a
particular patient.
Receptor tyrosine kinases are often aberrantly activated in
human cancers. In breast cancer, constitutive activation of
the epidermal growth factor receptor (EGFR) and ErbB2 is
often found. Aberrant activation results from overexpres-
sion, mainly due to gene amplification, kinase domain mu-
tation and autocrine or paracrine ligand induced activation.
The ERBB receptors couple to multiple signalling pathways
that impact on all aspect of cancer biology. Trastuzumab, an
ErbB2 specific humanized monoclonal antibody was one of
the first biologicals to be approved for metastatic breast
cancer treatment [3]. Recently, very exciting results from
three multicenter trials testing trastuzumab in the adjuvant
setting reported that addition of the antibody to standard
adjuvant chemotherapy was associated with a dramatic
reduction in the risk to recurrence [4]. The articles by
Gullick and colleagues and by Badache and Goncalves, on
EGFR and ErbB2, respectively, review the roles for these
receptors in breast cancer biology and as cancer targets.
Sachdev and Yee discuss the IGF receptor, another
important signal transducer in breast cancer.
mTOR is a central regulator of cellular responses to
multiple stimuli including amino acid availability and growth
factor receptor signaling. In cells with sufficient nutrients,
mTOR relays a signal to the translational machinery leading to
an enhanced translation of mRNAs encoding proteins
essential for cell growth and cell cycle progression [5]. In
breast tumors, activating mutations in PIK3A, encoding the
catalytic subunit of PI3K, or loss of PTEN, the negative
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regulator of PI3K activity, are very frequent and contribute
to constitutive pathway activation and mTOR activity.
The mTOR pathway and emerging opportunities for inter-
vention are the topic of a review by Hynes and Boulay.
The STATs are a family of transcription factors that relay
the interactions of cytokines and growth factors with their
receptors at the cell surface to mediate changes in gene
expression. In normal situations STATs are transiently
activated; however, in many tumors tyrosine-phosphorylated
STATs, mainly STAT3 and STAT5, can be detected,
suggesting constitutive pathway activation. The review by
Groner and colleagues discusses STAT functions and their
potential as therapeutic targets.
The NF-κB pathway is triggered in response to microbial
and viral infections and to pro-inflammatory cytokines. These
agents activate the IκB kinase, which phosphoylates IκB
allowing the liberated NF-κB family transcription factors to
enter the nucleus. The pathway has an ever increasing interest
for its role in human cancer (reviewed in [6]). The association
of NF-κB pathway activity with inflammation-associated
tumor progression is well documented in mouse tumor
models [7] and in human cancer cells [8]. Doppler and
colleagues discuss the NF-κB pathway in the context of
breast cancer, describing potential approaches to block the
pathway in tumors.
The Notch network in mammals consists of four Notch
receptors and five Delta-like and Jagged ligands. Once
activated, the receptor undergoes intramembrane proteolysis
leading to release and nuclear translocation of the intracellular
domain, which has transcriptional activity. The Notch-4 gene
is frequently rearranged in mammary glands by MMTV
proviral integration. This rearrangement leads to expression of
the intracellular domain under MMTV promoter control and
to mammary cancer [9], an early demonstration of Notch_s
ability to induce mammary cancer. In this issue Shi and
Harris discuss the role of Notch signaling in promotion of
tumor angiogenesis.
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